
Opinion|Videos|June 5, 2024
Evolving Commercialization and Distribution Models for PDTs
The panel discusses the challenges of delivering prescription digital therapeutics (PDTs) to patients, challenges caused by PDTs being considered behavioral health benefits, pharmacy benefits, medical benefits, and durable medical equipment benefits.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on AJMC
1
MFN Drug Agreements Could Raise Prices Worldwide
2
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
3
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
4
FDA Clears First Alzheimer Blood Test for Adults as Young as 40
5



